×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
NASDAQ:SNGX

Soligenix (SNGX) Stock Forecast, Price & News

$0.60
+0.04 (+7.16%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.56
$0.60
50-Day Range
$0.40
$0.75
52-Week Range
$0.38
$1.34
Volume
77,206 shs
Average Volume
140,712 shs
Market Capitalization
$25.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.28
30 days | 90 days | 365 days | Advanced Chart
Receive SNGX News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

Soligenix logo

About Soligenix

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Headlines

SNGX: NDA Filing for HyBryte™ in 2022…
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNGX
Employees
13
Year Founded
1987

Sales & Book Value

Annual Sales
$820 thousand
Book Value
$0.15 per share

Profitability

Net Income
$-13.42 million
Net Margins
-1,710.71%
Pretax Margin
-1,812.12%

Debt

Price-To-Earnings

Miscellaneous

Free Float
41,810,000
Market Cap
$25.79 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/29/2022
Today
5/29/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

1.97 out of 5 stars

Medical Sector

627th out of 1,429 stocks

Pharmaceutical Preparations Industry

291st out of 683 stocks

Analyst Opinion: 3.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













Soligenix (NASDAQ:SNGX) Frequently Asked Questions

Is Soligenix a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Soligenix in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Soligenix stock.
View analyst ratings for Soligenix
or view top-rated stocks.

When is Soligenix's next earnings date?

Soligenix is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Soligenix
.

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) released its earnings results on Tuesday, March, 29th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.03. The biopharmaceutical company earned $0.28 million during the quarter, compared to analyst estimates of $0.20 million. Soligenix had a negative net margin of 1,710.71% and a negative trailing twelve-month return on equity of 121.28%.
View Soligenix's earnings history
.

What price target have analysts set for SNGX?

2 analysts have issued 1-year price objectives for Soligenix's shares. Their forecasts range from $1.50 to $3.75. On average, they expect Soligenix's share price to reach $2.63 in the next year. This suggests a possible upside of 338.2% from the stock's current price.
View analysts' price targets for Soligenix
or view top-rated stocks among Wall Street analysts.

Who are Soligenix's key executives?
Soligenix's management team includes the following people:
What other stocks do shareholders of Soligenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM).

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

Who are Soligenix's major shareholders?

Soligenix's stock is owned by a variety of retail and institutional investors. Top institutional investors include ARGI Investment Services LLC (0.11%). Company insiders that own Soligenix stock include Christopher J Schaber, Jerome B Zeldis, Jonathan L Guarino and Richard Straube.
View institutional ownership trends for Soligenix
.

Which institutional investors are buying Soligenix stock?

SNGX stock was acquired by a variety of institutional investors in the last quarter, including ARGI Investment Services LLC. Company insiders that have bought Soligenix stock in the last two years include Christopher J Schaber, Jerome B Zeldis, Jonathan L Guarino, and Richard Straube.
View insider buying and selling activity for Soligenix
or or view top insider-buying stocks.

How do I buy shares of Soligenix?

Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soligenix's stock price today?

One share of SNGX stock can currently be purchased for approximately $0.60.

How much money does Soligenix make?

Soligenix has a market capitalization of $25.79 million and generates $820 thousand in revenue each year. The biopharmaceutical company earns $-13.42 million in net income (profit) each year or ($0.350010) on an earnings per share basis.

How many employees does Soligenix have?

Soligenix employs 13 workers across the globe.

When was Soligenix founded?

Soligenix was founded in 1987.

What is Soligenix's official website?

The official website for Soligenix is www.soligenix.com.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at (609) 538-8200, via email at [email protected], or via fax at 609-452-6467.

This page was last updated on 5/29/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.